Synopsis: The shares of this pharmaceutical company gained attention after it announced a Rs. 231.87 crore acquisition to take full ownership of its biologics subsidiary and strengthen its biotechnology business.
The shares of this company, which develops, manufactures, and globally markets a broad range of pharmaceutical and biopharmaceutical products gained investor traction after acquisition announcement.
With a market capitalization of Rs 34,309 crore, Emcure Pharmaceuticals Ltd’s share on Tuesday made a day high of Rs 1,839.90 per share, up by 2.7 percent from its previous day’s close price of Rs 1,792.45 per share. The share of the company gave a return of 33 percent over the last year.
Acquisition Details
Emcure Pharmaceuticals Ltd. has signed share purchase agreements to acquire the remaining 12.05 percent stake in its subsidiary, Gennova Biopharmaceuticals Ltd., from all its individual shareholders. The acquisition involves the purchase of 663,865 equity shares for a total cash consideration of Rs. 2,318.7 million (around Rs. 231.87 crore), which will be paid in one or more tranches. The transaction is expected to be completed on or before July 31, 2026.
Before the deal, Emcure held 87.95 percent of Gennova. Once the acquisition is completed, Gennova will become a wholly owned subsidiary of Emcure with 100 percent ownership. Since Gennova is already an Emcure subsidiary, the transaction qualifies as a related-party transaction. A promoter and director of Emcure also serves as a director and shareholder of Gennova, while some of their relatives are shareholders. However, the company stated that the transaction is being carried out on an arm’s length basis, and no regulatory approvals are required.
Gennova Biopharmaceuticals, incorporated in 2001, is engaged in the research, development, manufacturing, and marketing of biotechnology-based pharmaceutical products in India. For FY26, the company reported a turnover of Rs. 491.74 crore and a profit after tax of Rs. 5.43 crore. Its turnover has grown steadily over the last three years, rising from Rs. 422.08 crore in FY24 to Rs. 429.95 crore in FY25, and Rs. 491.74 crore in FY26. The acquisition strengthens Emcure’s ownership and gives it complete control over Gennova’s operations and future growth.
Management Outlook:
Emcure Managing Director and CEO Satish Mehta said the acquisition simplifies Gennova’s ownership structure and strengthens its strategic focus. He added that the company is well-positioned for its next phase of growth in biologics and biosimilars under the leadership of Samit Mehta.
Samit Mehta, Whole Time Director and CEO of Gennova Biopharmaceuticals, said the company will continue to strengthen Emcure’s biologics and biosimilars business under the ‘One Emcure’ framework. Emcure also said the acquisition will not impact its financials, capital allocation, capex, or R&D plans.
About the Company
Incorporated in 1981, Emcure Pharmaceuticals Ltd is a major Indian multinational pharmaceutical company headquartered in Pune, Maharashtra, that develops, manufactures, and globally markets a broad range of pharmaceutical and biopharmaceutical products. It specializes in therapies such as gynaecology, cardiovascular, oncology, HIV antivirals, and blood-related disorders.
Financial Highlight: Revenue from operations of Rs. 2,470 crore, compared to Rs. 2,116 crore in Q4 FY25, marking a 16.73 percent YoY growth. Operating margin remained stable at 19 percent in both Q4 FY26 and Q4 FY25. Net profit increased 23.86 percent YoY to Rs. 244 crore in Q4 FY26, from Rs. 197 crore in Q4 FY25, while earnings per share rose 28.79 percent to Rs. 12.84 in Q4 FY26, compared to Rs. 9.97 in Q4 FY25.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
